Risk register, issues, decision log and cross-record dependencies. Exposure is probability × impact on a 1–5 scale.
Open risks
Open issues
Decisions awaiting leadership
Dependencies blocked / at risk
Count of risks in the current filter by probability (columns) and impact (rows).
| Impact ↓ | P1 | P2 | P3 | P4 | P5 |
|---|---|---|---|---|---|
| I5 | 0 risks at exposure 5 | 0 risks at exposure 10 | 0 risks at exposure 15 | 0 risks at exposure 20 | 0 risks at exposure 25 |
| I4 | 0 risks at exposure 4 | 0 risks at exposure 8 | 0 risks at exposure 12 | 0 risks at exposure 16 | 0 risks at exposure 20 |
| I3 | 0 risks at exposure 3 | 0 risks at exposure 6 | 0 risks at exposure 9 | 0 risks at exposure 12 | 0 risks at exposure 15 |
| I2 | 0 risks at exposure 2 | 0 risks at exposure 4 | 0 risks at exposure 6 | 0 risks at exposure 8 | 0 risks at exposure 10 |
| I1 | 0 risks at exposure 1 | 0 risks at exposure 2 | 0 risks at exposure 3 | 0 risks at exposure 4 | 0 risks at exposure 5 |
Probability → · Exposure = P × I. High (≥ 12): 0 · Medium (6–11): 0 · Low (< 6): 0 · 0 risks shown.
No records match the current filters
No records match the current filters
DEC-0010v1VantrexaNeeds leadership
Formally sponsor a Phase IV brain-metastasis study concept (EVP-0002).
INS-0047 and 6 related insights from US centres.
Options considered
Follow-ups (0)
None recorded.
0 blocked · 0 at risk · 1 on track · 0 resolved. Product filter does not apply to dependencies.
| ID | Dependent | Prerequisite | Type | Owner | Due | Status | Impact if delayed | Resolution plan | |
|---|---|---|---|---|---|---|---|---|---|
| DEP-0008 | Brain-metastasis Phase IV Evidence project · EVP-0002 | Sponsor Phase IV concept Decision · DEC-0010 | Internal | PRDr. Priya Raman | 15 Oct 2026 | On track | Evidence gap remains open through 2027 | — |